By Fineline Cube 
BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to BeOne Medicines Ltd. and relocated its domicile to Switzerland, effective immediately. This strategic move underscores the company’s commitment to enhancing its global presence and operational efficiency.
Shareholder Approval and Implementation
The decision to adopt the new name and relocate from the Cayman Islands was approved by shareholders on April 28, 2025. The rebranding initiative will be implemented across BeOne’s operations on six continents in a phased manner.
R&D and Clinical Development
BeOne Medicines boasts an entrepreneurial R&D team exceeding 1,100 members. In 2024 alone, the company advanced 13 novel molecular entities into clinical trials. Its clinical development team, comprising nearly 3,700 professionals, is actively conducting or planning trials in over 45 countries and regions. To date, the team has enrolled more than 25,000 patients across 170 trials.
Investment in Infrastructure
To support its rapidly growing pipeline, BeOne is investing USD 800 million to construct a flagship clinical R&D and manufacturing facility in New Jersey, USA. This investment highlights the company’s dedication to expanding its research and development capabilities and meeting the growing demand for its oncology therapies.-Fineline Info & Tech